![]() |
![]() |
![]() |
![]() |
![]() |
![]() |


Team Leader - Epigenetics Cellular Screening
Panagiotis (Takis) completed his Ph.D. in Human Genetics and Developmental Biology from the University of Connecticut Health Center, Farmington, CT in 1998. After a post-doc on Molecular & Cellular Biology at IRCM in Montreal where he studied signaling pathways and control of gene expression during early embryonic development, he joined Aurelium BioPharma as senior scientist where he led the Cell Biology-Target Validation group from 2002-2006. During the next 5 years, he managed a Genome Canada project on the functional annotation of essential alternatively spliced isoforms in cancer at the Universite de Sherbrooke, Quebec. Subsequently, he directed the functional genomics/phenotypic platform at the Laboratory for Functional Genomics in Sherbrooke, Quebec. He joined the SGC in December 2014 where he is leading the Oncology patient-derived tumor cell screening activities.
Takis' current interests include cell-based assays and phenotypic screening, assay development and validation, HCS/HTS screens and epigenetic pathways in tumorigenesis, RNA splicing and metabolism, cell survival and proliferation.
Nat Chem Biol. 2022 . doi: 10.1038/s41589-022-01024-4
PMID: 35578032
Front Cell Neurosci. 2022 16:809917. doi: 10.3389/fncel.2022.809917
PMID: 35295905
Nat Commun. 2021 12(1):979. doi: 10.1038/s41467-021-21204-5
PMID: 33579912
Cancer Res. 2021 81(9):2457-2469. doi: 10.1158/0008-5472.CAN-20-2489
PMID: 33574085
Nat Commun. 2020 11(1):4205. doi: 10.1038/s41467-020-18020-8
PMID: 32826891
2023
Methods Mol Biol. 10.08.2023 2706:201-214. doi: 10.1007/978-1-0716-3397-7_15
PMID: 37558951
F1000Res. 07.08.2023 12:308. doi: 10.12688/f1000research.131333.1
PMID: 37545650
2022
Nat Rev Urol. 17.10.2022 . doi: 10.1038/s41585-022-00659-1
PMID: 36253570
Nat Chem Biol. 16.05.2022 . doi: 10.1038/s41589-022-01024-4
PMID: 35578032
Front Cell Neurosci. 18.03.2022 16:809917. doi: 10.3389/fncel.2022.809917
PMID: 35295905
2021
Cancer Res. 01.05.2021 81(9):2457-2469. doi: 10.1158/0008-5472.CAN-20-2489
PMID: 33574085
Nat Commun. 12.02.2021 12(1):979. doi: 10.1038/s41467-021-21204-5
PMID: 33579912
2020
Nat Commun. 21.08.2020 11(1):4205. doi: 10.1038/s41467-020-18020-8
PMID: 32826891
Cell. 20.05.2020 . doi: 10.1016/j.cell.2020.04.047
PMID: 32445698
2017
Nature. 30.08.2017 . doi: 10.1038/nature23666
PMID: 28854171
Cell Stem Cell. 11.07.2017 . doi: 10.1016/j.stem.2017.06.004
PMID: 28712938
2016
Meth. Enzymol.. 16.02.2016 574:79-103. doi: 10.1016/bs.mie.2016.01.011
PMID: 27423858
2015

Nat Rev Drug Discov. 20.02.2015 14(3):149-50. doi: 10.1038/nrd4565
PMID: 25722227
2014
RNA. 02.2014 20(2):189-201. doi: 10.1261/rna.042168
PMID: 24335142
2013
Nat Commun. 2013 4:2480. doi: 10.1038/ncomms3480
PMID: 24048253
Cancer Treat Res. 2013 158:41-94. doi: 10.1007/978-3-642-31659-3_3
PMID: 24222354
Mol Cell Biol. 2013 33(2):396-405. doi:
PMID:
2012
Med Sci. 11.15.2012 Vol. 1, 4, . doi:
PMID:
Mol Cell Biol. 03.15.2012 32(5):954-67. doi: 10.1128/MCB.06130-11
PMID: 22203037
2011
Int J Biochem Mol Biol. 2011 2(1): 24-30. doi:
PMID: 21968505
Nat Struct Mol Biol. 06.18.2011 18(6):673-9. doi: 10.1038/nsmb.2040
PMID: 21552259